We have located links that may give you full text access.
Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis.
British Journal of Dermatology 2018 March
BACKGROUND: Hidradenitis suppurativa (HS) has been linked to Down syndrome (DS).
OBJECTIVES: To determine whether patients with DS have a higher prevalence of HS, and whether the diagnosis of HS occurs at an earlier age for these patients.
METHODS: A cross-sectional analysis was performed for a population sample of 11 936 patients with DS and 16 813 290 patients without DS. The primary outcome was the diagnosis of HS. Systemized Nomenclature of Medicine-Clinical Terms were used to identify patients with DS and HS. We used logistic regression models and significant interaction terms to evaluate the relationship between DS and HS. We also compared the proportion of incident HS cases within 5-year age groups to determine whether patients with DS had received an earlier diagnosis of HS.
RESULTS: Prevalence of HS among patients with DS was 2·1%, compared with 0·3% for patients without DS (P < 0·001). HS prevalence was greatest among patients with DS who were aged 18-29 years. After controlling for age, sex and obesity, there was no difference in the prevalence of HS between female and male patients with DS or between white and nonwhite patients with DS. Compared with patients without DS, patients with DS had increased odds of HS in unadjusted [odds ratio (OR) 7·84, 95% confidence interval (CI) 6·93-8·88] and adjusted (OR 5·24, 95% CI 4·62-5·94) analyses. HS was diagnosed by the age of 29 years in 81·8% of patients with DS, compared with 34·0% of patients without DS (P < 0·001).
CONCLUSIONS: HS is strongly associated with DS across demographic subgroups and may present earlier in life for these patients.
OBJECTIVES: To determine whether patients with DS have a higher prevalence of HS, and whether the diagnosis of HS occurs at an earlier age for these patients.
METHODS: A cross-sectional analysis was performed for a population sample of 11 936 patients with DS and 16 813 290 patients without DS. The primary outcome was the diagnosis of HS. Systemized Nomenclature of Medicine-Clinical Terms were used to identify patients with DS and HS. We used logistic regression models and significant interaction terms to evaluate the relationship between DS and HS. We also compared the proportion of incident HS cases within 5-year age groups to determine whether patients with DS had received an earlier diagnosis of HS.
RESULTS: Prevalence of HS among patients with DS was 2·1%, compared with 0·3% for patients without DS (P < 0·001). HS prevalence was greatest among patients with DS who were aged 18-29 years. After controlling for age, sex and obesity, there was no difference in the prevalence of HS between female and male patients with DS or between white and nonwhite patients with DS. Compared with patients without DS, patients with DS had increased odds of HS in unadjusted [odds ratio (OR) 7·84, 95% confidence interval (CI) 6·93-8·88] and adjusted (OR 5·24, 95% CI 4·62-5·94) analyses. HS was diagnosed by the age of 29 years in 81·8% of patients with DS, compared with 34·0% of patients without DS (P < 0·001).
CONCLUSIONS: HS is strongly associated with DS across demographic subgroups and may present earlier in life for these patients.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app